Sunny Competitors

Stocks . Taiwan . 
Stock . Sunny Pharmtech
6676 Stock   16.00  0.60  3.90%   
Sunny Pharmtech competes with Genomics BioSci, Chunghwa Chemical, GlycoNex, Enimmune Corporation, and Intech Biopharm; as well as few others. Analyzing Sunny Pharmtech competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Sunny Pharmtech to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

Sunny Pharmtech vs Meribank Biotech Correlation

Very good diversification

The correlation between Sunny Pharmtech and 4724 is -0.29 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Sunny Pharmtech and 4724 in the same portfolio, assuming nothing else is changed.

Moving against Sunny Stock

  0.592882 Cathay Financial HoldingPairCorr
  0.482454 MediaTekPairCorr
  0.321303 Nan Ya PlasticsPairCorr

Sunny Pharmtech Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Sunny Pharmtech and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Sunny and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Sunny Pharmtech does not affect the price movement of the other competitor.

High positive correlations

6461
+ 0.8
4168
6564
+ 0.46
4168
6461
+ 0.44
1762
4168
+ 0.41
1762
6934
+ 0.32
1762
4168
+ 0.31
4195
  

High negative correlations

4724
- 0.63
6934
4168
- 0.62
6709
6461
- 0.55
6709
6846
- 0.45
4195
6564
- 0.37
6709
4724
- 0.32
6709

Risk-Adjusted Indicators

There is a big difference between Sunny Stock performing well and Sunny Pharmtech Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Sunny Pharmtech's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
4195  1.34 (0.08) 0.00 (0.30) 0.00 
 0.00 
 3.80 
(2.91)
 8.92 
1762  0.66  0.04 (0.04) 0.40  0.60 
(1.04)
 1.63 
(1.16)
 4.75 
6709  1.71 (0.32) 0.00 (0.56) 0.00 
 0.00 
 3.20 
(3.71)
 16.90 
6846  0.74  0.00 (0.04) 0.07  0.91 
(1.01)
 1.91 
(1.71)
 5.90 
6934  4.73  2.08  0.37 (3.54) 3.17 
(5.54)
 18.06 
(8.04)
 45.51 
4168  1.85  0.37  0.12 (3.64) 1.95 
(2.29)
 7.23 
(2.70)
 18.02 
6827  1.71 (0.40) 0.00 (0.91) 0.00 
 0.00 
 3.19 
(7.93)
 13.44 
6564  1.43  0.01 (0.04)(0.14) 1.49 
(1.88)
 4.78 
(2.93)
 9.31 
6461  2.69  0.46  0.13 (0.96) 2.21 
(4.11)
 9.86 
(5.00)
 16.28 
4724  1.40 (0.15) 0.00 (0.66) 0.00 
 0.00 
 5.26 
(3.72)
 14.75 

Sunny Pharmtech Competitive Analysis

The better you understand Sunny Pharmtech competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Sunny Pharmtech's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Sunny Pharmtech's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
6676 4195 1762 6709 6846 6934 4168 6827 6564 6461
 3.90 
 16.00 
Sunny
 1.84 
 24.85 
Genomics
 3.68 
 26.80 
Chunghwa
 1.94 
 28.90 
Advagene
 0.27 
 74.30 
Greenyn
 4.75 
 140.50 
6934
 1.91 
 28.25 
GlycoNex
 0.40 
 12.40 
MegaPro
 3.13 
 20.10 
Enimmune
 0.70 
 21.15 
Intech
Market Volatility
(90 Days Market Risk)
Somewhat reliable
Very steady
Very steady
Very steady
Very steady
Very steady
Not too volatile
Somewhat reliable
Not too volatile
Out of control
Market Performance
(90 Days Performance)
Fair
Weakest
Soft
Weakest
Weak
Solid
Fair
Weakest
Weakest
Fair
Odds of Financial Distress
(Probability Of Bankruptcy)
Unknown
Low
Low
Fair
Unknown
Unknown
Moderate
Unknown
High
Fair
Current Valuation
(Equity Enterprise Value)
Over Valued
Fairly Valued
Fairly Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Hold
Strong Hold
Strong Hold
Strong Buy
Strong Sell
Strong Sell
Cautious Hold
Cautious Hold
Not Rated
Current Ratio
N/A
3.01
1.36
N/A
N/A
N/A
N/A
N/A
15.1
N/A
Net Asset
N/A
N/A
4.38 B
N/A
N/A
N/A
1.4 B
N/A
N/A
2.6 B
Profit Margin
N/A
N/A
0.23
N/A
N/A
N/A
N/A
N/A
-81.58
N/A
EBITDA
N/A
25.55 M
632.93 M
N/A
N/A
N/A
(132.36 M)
N/A
(66.03 M)
(196.92 M)
Operating Margin
N/A
N/A
0.22
N/A
N/A
N/A
-6.59
N/A
-101.32
-9.09
Current Valuation
N/A
N/A
5.19 B
N/A
N/A
N/A
3.05 B
N/A
1.94 B
5.09 B
Price To Book
N/A
N/A
1.56
N/A
N/A
N/A
2.37
N/A
3.96
3.67
Retained Earnings
N/A
N/A
630 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Asset
N/A
N/A
729 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Five Year Return
N/A
N/A
2.83
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
N/A
0.64
0.86
N/A
N/A
N/A
1.07
N/A
0.37
0.59
Number Of Employees
N/A
16
21
10
N/A
N/A
13
N/A
27
87
Shares Outstanding
N/A
N/A
77.56 M
N/A
N/A
N/A
107.1 M
N/A
60 M
116.96 M
Cash Flow From Operations
N/A
40.87 M
219.18 M
N/A
N/A
N/A
(141.08 M)
N/A
(114.54 M)
(200.61 M)
Annual Yield
N/A
N/A
0.0198
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
N/A
86.52 M
600 M
N/A
N/A
N/A
N/A
N/A
7.97 M
940.77 M
Return On Equity
N/A
N/A
0.17
N/A
N/A
N/A
-0.14
N/A
-9.41
-0.28
Z Score
N/A
9.0
4.8
N/A
N/A
N/A
N/A
N/A
N/A
1.8
Book Value Per Share
N/A
12.89
39.98
N/A
N/A
N/A
14.6
N/A
10.29
9.61
Return On Asset
N/A
N/A
0.066
N/A
N/A
N/A
-0.0844
N/A
-6.93
-0.0739
Current Liabilities
N/A
N/A
617 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Asset
N/A
N/A
4.38 B
N/A
N/A
N/A
1.4 B
N/A
N/A
2.6 B
Debt To Equity
N/A
0.11
41.0
N/A
N/A
N/A
N/A
N/A
0.013
N/A
Last Dividend Paid
N/A
1.17
1.3
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Target Price
N/A
N/A
125.0
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
N/A
N/A
4.61
N/A
N/A
N/A
0.1
N/A
N/A
6.26
Market Capitalization
N/A
1.34 B
5.17 B
879.46 M
N/A
N/A
3.43 B
N/A
2.44 B
3.71 B
Price To Earning
N/A
26.25
9.2
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
N/A
N/A
2.37
N/A
N/A
N/A
111.08
N/A
33.44
128.48
Net Income
N/A
45.34 M
400.78 M
N/A
N/A
N/A
(172.49 M)
N/A
(59.64 M)
(301.76 M)
Earnings Per Share
N/A
0.72
6.21
N/A
N/A
N/A
-1.66
N/A
-1.4
-2.87
Shares Owned By Insiders
N/A
N/A
39.75
N/A
N/A
N/A
21.44
N/A
N/A
47.02
Revenue
N/A
N/A
1.93 B
N/A
N/A
N/A
5.47 M
N/A
73.11 M
38.9 M
Working Capital
N/A
N/A
112 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
N/A
110.98 M
97.43 M
N/A
N/A
N/A
N/A
N/A
390.32 M
N/A
Cash Per Share
N/A
1.76
1.26
N/A
N/A
N/A
N/A
N/A
6.51
N/A
Gross Profit
N/A
N/A
949.39 M
N/A
N/A
N/A
3.46 M
N/A
8.22 M
(119.37 M)
Day Typical Price
15.75
25.03
26.5
28.83
74.4
143.33
28.6
12.33
20.3
21.03
Accumulation Distribution
8438.42
13580.37
5636.08
2392.76
289.87
29857.96
20471.88
1769.25
2960.55
12880.47
Daily Balance Of Power
0.6316
0.3333
1.055556
0.55
(0.22)
(0.74)
(0.52)
(0.17)
(1.08)
(0.20)
Period Momentum Indicator
0.6
0.45
0.95
0.55
(0.20)
(7.00)
(0.55)
(0.05)
(0.65)
(0.15)
Rate Of Daily Change
1.04
1.02
1.04
1.02
1.0
0.95
0.98
1.0
0.97
0.99
Day Median Price
15.63
25.13
26.35
28.8
74.45
144.75
28.78
12.3
20.4
20.98
Price Action Indicator
0.67
(0.05)
0.93
0.37
(0.25)
(7.75)
(0.80)
0.075
(0.62)
0.1
Relative Strength Index
N/A
46.39
67.04
52.02
51.19
N/A
61.31
N/A
N/A
59.15
Coefficient Of Variation
825.88
(3,344)
1854.27
(980.02)
2979.95
371.55
797.66
(816.01)
10450.6
887.78
Mean Deviation
2.23
1.34
0.6556
1.71
0.7438
4.73
1.85
1.71
1.43
2.69
Jensen Alpha
0.4393
(0.08)
0.0351
(0.32)
(0)
2.08
0.3655
(0.40)
0.0138
0.4599
Total Risk Alpha
0.0788
(0.24)
(0.05)
(0.54)
(0.08)
1.3
0.0743
(0.65)
(0.18)
0.0521
Sortino Ratio
0.1414
N/A
(0.04)
N/A
(0.04)
0.3747
0.1247
N/A
(0.04)
0.131
Downside Variance
6.47
N/A
0.6278
N/A
1.09
27.51
5.32
N/A
2.46
7.43
Standard Deviation
3.64
1.84
0.9787
2.65
1.07
7.6
2.94
2.93
2.0
3.89
Kurtosis
12.26
1.19
4.37
8.02
1.63
9.03
3.52
7.15
3.57
1.43
Potential Upside
5.26
3.8
1.63
3.2
1.91
18.06
7.23
3.19
4.78
9.86
Treynor Ratio
(3.54)
(0.30)
0.3968
(0.56)
0.0676
(3.54)
(3.64)
(0.91)
(0.14)
(0.96)
Maximum Drawdown
22.1
8.92
4.75
16.9
5.9
45.51
18.02
13.44
9.31
16.28
Variance
13.24
3.4
0.9578
7.0
1.14
57.82
8.64
8.57
3.99
15.13
Market Risk Adjusted Performance
(3.53)
(0.29)
0.4068
(0.55)
0.0776
(3.53)
(3.63)
(0.90)
(0.13)
(0.95)
Risk Adjusted Performance
0.0968
(0.02)
0.0421
(0.07)
0.0277
0.2065
0.0995
(0.08)
0.0133
0.0908
Skewness
2.76
0.6446
1.6
1.81
(0.03)
2.36
1.0
0.6741
1.38
1.26
Semi Deviation
1.99
N/A
0.5994
N/A
0.9068
3.17
1.95
N/A
1.49
2.21
Information Ratio
0.0988
(0.07)
(0.03)
(0.13)
(0.04)
0.2585
0.0978
(0.15)
(0.03)
0.0918
Value At Risk
(4.47)
(2.91)
(1.16)
(3.71)
(1.71)
(8.04)
(2.70)
(7.93)
(2.93)
(5.00)
Expected Short fall
(2.99)
N/A
(1.04)
N/A
(1.01)
(5.54)
(2.29)
N/A
(1.88)
(4.11)
Downside Deviation
2.54
N/A
0.7923
N/A
1.04
5.25
2.31
N/A
1.57
2.73
Semi Variance
3.96
N/A
0.3593
N/A
0.8223
10.08
3.8
N/A
2.23
4.87

Sunny Pharmtech Competition Performance Charts

Five steps to successful analysis of Sunny Pharmtech Competition

Sunny Pharmtech's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Sunny Pharmtech in relation to its competition. Sunny Pharmtech's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Sunny Pharmtech in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Sunny Pharmtech's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Sunny Pharmtech, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Sunny Pharmtech position

In addition to having Sunny Pharmtech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small Blend Funds Thematic Idea Now

Small Blend Funds
Small Blend Funds Theme
Fund or Etfs that invest in stocks of small to mid-sized entities that have characteristics of both growth and value companies. The Small Blend Funds theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Blend Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Sunny Stock Analysis

When running Sunny Pharmtech's price analysis, check to measure Sunny Pharmtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunny Pharmtech is operating at the current time. Most of Sunny Pharmtech's value examination focuses on studying past and present price action to predict the probability of Sunny Pharmtech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunny Pharmtech's price. Additionally, you may evaluate how the addition of Sunny Pharmtech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY